Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;42(2):353-363.
doi: 10.1007/s11095-025-03825-3. Epub 2025 Feb 20.

In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss

Affiliations

In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss

Richa Garg et al. Pharm Res. 2025 Feb.

Abstract

Objective: Biologic drug molecules such as antibodies are exposed to the physiological stress conditions of pH 7.4 and 37°C during their long circulation lifetime in vivo. The stress on biologic molecules in vivo is more severe compared to that under typical storage conditions of low pH formulation and cold temperature. Chemical degradation of critical residues such as asparagine may occur in vivo, leading to potential loss of biological activity. This study describes a physiologically relevant and convenient in vitro PBS stress condition of pH 7.4 and 40°C for pre-clinical stability screening of biologic molecules.

Methods: As benchmarks, multiple commercial antibodies (alirocumab, evolocumab, golimumab, ramucirumab, and trastuzumab) were tested in parallel for formulation stability at storage and accelerated temperature conditions and for physiological stability at pH 7.4 and 40°C stress both for 3-4 weeks. The stressed antibodies were monitored for chemical modification and target binding, without requiring affinity purification.

Results: The major CDR chemical modifications observed in PBS-stressed commercial antibodies were deamidations of asparagine residues. Although slight decreases in target binding were observed for two antibodies, the affinities overall remained strong after PBS stress.

Conclusions: This benchmarking study of commercial antibodies would be useful as a guide to screen discovery-stage biologic molecules both for drug product stability at formulation pH under storage and accelerated temperature conditions and for physiological stability under in vivo-mimicking pH and temperature stress condition.

Keywords: PBS; antibodies; asparagine; deamidation; stress.

PubMed Disclaimer

Conflict of interest statement

Declarations. Disclosures: AbbVie funded the study and participated in study design, research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication. Jianwen Xu has no additional conflicts of interest to report and is currently affiliated with Kiniksa Pharmaceuticals. Richa Garg, Sean McCarthy, Alayna George Thompson, Jiang Zhang, Emily Mattson, Anca Clabbers, Aimalohi Acquah, Chen Zhou, Amr Ali, Dana Filoti, Rajeeva Singh are employees of AbbVie and may own AbbVie stock.

Figures

Fig. 1
Fig. 1
Potential in vivo modification sites of antibody. (A). Antibody regions reported to undergo modification in vivo. (B). Asparagine (Asn) deamidation and aspartate (Asp) isomerization pathway.
Fig. 2
Fig. 2
icIEF of antibody samples stressed in PBS, pH 7.4, 40°C (2 mg/mL). Main, acidic, and basic species are shown by change in area % (14 and 28 day).
Fig. 3
Fig. 3
Proposed scheme for in vitro PBS stability screening and CDR re-engineering of discovery-stage antibody candidates.

References

    1. Rao VA, Kim JJ, Patel DS, Rains K, Estoll CR. A Comprehensive Scientific Survey of Excipients Used in Currently Marketed, Therapeutic Biological Drug Products. Pharm Res. 2020;37:200. - PMC - PubMed
    1. Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20:491–5. - PubMed
    1. Gervais D. Protein deamidation in biopharmaceutical manufacture: understanding, control and impact. J Chem Technol Biotechnol. 2016;91:569–75.
    1. Guideline on development, production, characterisation and specification for monoclonal antibodies and related products. EMA. 2016.
    1. Ovacik M, Lin K. Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clin Transl Sci. 2018;11:540–52. - PMC - PubMed

LinkOut - more resources